Motzer, R J <br/><br/>
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Aug 2000 
 - 2972-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2000.18.16.2972  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Injections, Subcutaneous<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Isotretinoin--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Models, Statistical<br/>Multivariate Analysis<br/>Quality of Life<br/>Recombinant Proteins<br/>Statistics, Nonparametric<br/>Surveys and Questionnaires<br/>Survival Analysis<br/>Treatment Outcome